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Abstract 
Diets, through multiple mechanisms, cause significant impact on human health and disease 
etiology; proposed modes of action include modulation of non-coding RNAs and influences on 
the gut microbiome. Specifically, phytochemicals change human miRNA expression thereby 
impacting gut microbiome and/or increasing host immune functions. Apiaceous and cruciferous 
vegetables have been linked to decreased chronic inflammation, which is closely related with the 
host immune system, yet it is not investigated how these two classes of vegetables influence the 
colonic miRNA profile. In this study, therefore we aimed to determine the effects of short-term 
feeding of broccoli and carrot to infants on fecal miRNA. Three experimental groups were 
included: (1) control group (CON); (2) carrot group (CRT); and (3) broccoli group (BROC). 
Participants began the five-day study at six months of age. The puree diets (either broccoli or 
carrot puree) were introduced from Day 1 through Day 3 (i.e., 3 consecutive days: 2 oz per day). 
During the intervention period (Day 1 - Day 3), the CON group participants continued 
consuming breast milk and/or formula only. Diapers with stool were collected on Day 0, Day 2, 
and Day 4. Fecal RNA was isolated and then miRNA expression was profiled using the 
NanoString nCounter platform. Additionally, we subjected the miRNA results to Ingenuity 
Pathway Analysis (IPA) and Gene Ontology Protein Analysis Through Evolutionary 
Relationships (PANTHER) to predict enriched biological functions/molecular functions in 
broccoli- and carrot-fed infants. Compared to the CON group, 22 miRNAs and 20 miRNAs 
passed our criteria to be considered ‘differentially expressed’ from the CRT and BROC 
intervention groups, respectively. In our miRNA target prediction analyses, using IPA, a total of 
132 potential mRNA target transcripts were identified in the CRT group. Similarly, in the BROC 
group, a total of 101 potential mRNA target transcripts was predicted. In the subsequent 
PANTHER analyses, ‘Positive regulation of cellular response to macrophage colony-stimulating 
factor stimulus’ and ‘Positive regulation of response to macrophage colony-stimulating factor’; 
‘Interleukin-1, type I, activating receptor activity’; ‘Interleukin-1 receptor activity’; and 
‘Interleukin-1 receptor binding’ were found to be most significantly enriched in the CRT infants. 
On the other hand, in the BROC group, ‘Negative regulation of natural killer cell differentiation 
involved in immune response’; ‘Regulation of natural killer cell differentiation’; ‘Interleukin-1, 
type I, activating receptor activity’; ‘Interleukin-1 receptor activity’; and ‘Interleukin-1 receptor 
binding’ were enriched the most. Overall, our study provides evidence that CRT and BROC 
intervention impacts human infants’ miRNAs and may lead to overall benefits in their immune 
system likely through different miRNA, predicted mRNA target transcripts, and 
molecular/biological functions. 
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Chapter 1  
Review of Literature 
What is MicroRNA? 
Diet elicits significant impacts on human health and disease etiology with numerous 
mechanisms thus far proposed; modulation of non-coding RNAs is one of them (1). MicroRNAs 
(miRNAs) are one class of small non-coding RNAs (ncRNAs) and are mostly 20-22 nucleotides 
in length. MiRNAs are the most abundant class of non-coding RNAs; these small RNAs inhibit 
gene expression at the post-transcriptional level (2). Specifically, miRNAs are able to repress the 
translation process of mRNA into proteins via perfect and/or imperfect base-pairing binding 
thereby inducing mRNA degradation. As it is estimated that approximately one third of all 
human genes is impacted by this class of small RNAs, it is not surprising that miRNAs play 
pivotal roles in key biological processes; these include development, differentiation, cell death, 
and proliferation (3). 
 
Biogenesis of MicroRNAs 
Small ncRNAs can be divided into a few sub-classes: short interfering RNAs, miRNAs, Piwi-
interacting RNAs, repeat-associated small interfering RNAs, natural antisense transcript-derived 
siRNA, trans-acting siRNA, and tiny ncRNAs (4). MiRNAs are the largest class in human tissues, 
and are produced by a collective machinery of RNase III proteins [i.e., Drosha, and Dicer (5)]. In 
humans, most miRNAs are encoded in intron regions, while some are present in exon regions (6). 
Precise miRNA promoters for most miRNAs have been identified through collective analyses of 
CpG islands and RNA sequencing data (7). MiRNAs often have multiple transcription start sites 
(7), and may occasionally have distinct promoters from their host genes (8). 
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Primary transcripts (also known as pri-RNA) are generated by RNA polymerase II, resulting 
in short hairpin RNAs (pre-miRNAs) which will form secondary structures to yield mature 
miRNAs (9; 10). After transcription, pre-RNAs undergo maturation steps to result in production of 
miRNAs via the canonical pathway. Processing in the nucleus of pre-miRNAs is mediated by an 
RNase III protein (Drosha), to predetermine the mature miRNA sequence via specific RNA 
cleavage (11; 12). Once translocated to the cytoplasm, other cytoplasmic RNase III proteins (i.e., 
Dicer) act on the pre-RNA to release a mature double-stranded miRNA (13; 14). Post Dicer 
processing, double-stranded miRNAs are unwound and “activated” via the incorporation into 
RNA-induced silencing complex (RISC). Association with RISC allows for the silencing 
capability of miRNA on target mRNA (15). 
In addition to the canonical pathway of miRNA biogenesis, there is a non-canonical pathway; 
which occurs when cells are deficient in DiGeorge syndrome critical region 8 (DGCRB), Drosha 
or Dicer, where miRNA can be produced in a microprocessor-independent manner (16; 17). The 
non-canonical pathway starts with the bypass of the Drosha-mediated processing step, and the 
pre-RNA is generated through mRNA splicing; this process bypasses the transcription-generated 
short hairpin RNAs (18). After the bypass, the pre-miRNA continues in the latter steps of the 
canonical pathway (19). However, most miRNAs are produced by the canonical pathway, and 
those produced by the non-canonical pathway tend to be low in number (5).  
 
Control Points of MicroRNAs 
There are multiple control points of miRNA biogenesis to fine-tune their expression and to 
control biological functions. Although not fully understood, several regulatory factors have been 
proposed thus far. The first possible regulatory mechanism includes Drosha binding proteins, 
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which either positively or negatively modulate Drosha-mediated processes (20; 21). Another 
possible control point relates to Drosha/DGCRB expression, which has been shown to alter 
expression levels of miRNA (22; 23). Expression of exportin-5 could also modulate levels of 
miRNAs; the exportin-5 is responsible for transport of miRNAs from nucleus to cytoplasm (24). 
In the cytoplasm, Dicer binding proteins [i.e., TAR RNA binding protein and protein kinase 
RNA activator] may regulate miRNAs through impacting the RISC assembly (25; 26). 
Additionally, studies suggest that epigenetic controls contribute to miRNA regulation as well (27). 
Specifically, miRNAs may be regulated through epigenetic control of multi-drug resistance-1, 
where miRNAs could be directly repressed (28). Lastly, genetic single nucleotide morphisms 
(SNPs) within the miRNA may alter the processing efficiency (29).  
Although there is convincing evidence showing that miRNA play a role in post-transcriptional 
regulations, specific mechanisms by which miRNAs control mRNA expression is still not fully 
understood. One possible mechanism is that miRNAs may inhibit mRNA initiation by interfering 
with the recognition of M7G-cap (30). Additionally, promotion to drop-off ribosomes by miRNA 
was a proposed mechanism of mRNA repression (31). Another proposed mechanism is through 
inhibition of actively translating polyribosomes (32). Lastly, miRNA-induced deadenylation may 
possibly result in mRNA decay in P-body, high levels of which are found in the components of 
mRNA decay pathway (33).   
In the following sections we discuss evidence of the potential for dietary elements, and their 
constituents, to regulate miRNA, and thereby influence target mRNA expression. As specific 
mechanisms between miRNA and mRNA remain relatively unknown, the mechanistic influence 
of diet remains unclear as well. Little is known of how miRNAs are impacted by diet, and of 
potential targeted regulatory mechanisms of dietary constituents. Further research is needed to 
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identify and solidify the mechanisms of miRNA control on mRNA, as well as the target 
mechanisms impacted via dietary interventions.  
 
Effects of Vegetables and Their Bioactives on MicroRNA  
Phytochemicals are a diverse group of plant-derived bioactive compounds, including but not 
limited to: polyphenols (i.e., flavonoids), carotenoids, glucosinolates, phytosterols, and allicins 
[reviewed in (34)]. In addition, plant secondary metabolites (e.g., polyphenols) are phytochemicals 
found in many plant foods, and are the most abundant source of antioxidants within the diet (35; 
36). Dietary sources of each phytochemical category are included in Table 1s. 
Accumulating evidence shows that dietary constituents influence miRNA expression, thereby 
resulting in an array of downstream mRNA expression changes. Specifically, polyphenols in 
fruits and vegetables alter miRNA expression. Phenolic constituents from mango were found to 
modulate inflammation by regulating the expression of miR-126. Kim et al. demonstrated that 
mango bioactives increased miR-126 expression which in turn suppressed the 
phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR)/protein kinase B 
(AKT) signaling axis (37). Another study showed that pomegranate ellagitannins and 
anthocyanins upregulated miR-126 expression and suppressed PI3K signaling, thereby reducing 
mucosal inflammation in carcinogen-treated rats (38). Last, blueberries, rich in polyphenols, 
showed an inhibition of atherosclerosis-related miRNAs (i.e., miRNAs miR-21, miR-146a, and 
miR-125b) when looking at the effect of polyphenol fractions in inflammation among RAW 
264.7 cells (39). In the context of inflammation, polyphenols from green tea (i.e., catechins) 
modulate the miRNA profile in white adipose tissue in mice fed a high-fat diet. Specifically, in 
adipose tissue, miR-335 is known to be upregulated by TNF-α, a proinflammatory cytokine(40). 
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However, the TNF-α-mediated upregulation of miR-335 in adipocytes was inhibited through 
catechins in green tea extract, and thereby reduced mRNA expression associated with insulin 
resistance and lipid metabolism (e.g., Insr, Irs1, Sirt1, and Foxo1). Thus, it is indicated that 
obesity leads to a pro-inflammatory state, and gene expression profiles associated with insulin 
resistance are counteracted by green tea extract catechins via miRNA regulation and increased 
lipolysis (40).  
In addition to polyphenols, in a recent study, Slaby et al. found that three miRNAs (miR-155, 
miR-23b, and miR-27b) were affected by iberin and sulforaphane (from the isothiocyanate class 
of dietary bioactives) in colon epithelial cell lines (NCM460 and NCM356)(41). This study 
showed possible roles of miRNAs in chemoprevention through targeting multiple genes 
harboring SNPs (e.g., AGTR1, TNFAIP2, and SIRT5). Interestingly, DICER1, a gene involved 
in the generation of miRNAs, was predicted as a target of miR-23b and was significantly 
associated with decreased risk of sporadic colorectal cancer (41). Similarly, in a recent study, 
butyrate, a metabolite of dietary fibers, was shown to regulate miRNAs; there was a reduction of 
miR-106b, which may be involved in inhibition of LT97 colon adenoma cell proliferation(42). 
The modification of miR-106b expression might contribute to the induction of cell cycle 
regulatory proteins, like p21, as a mechanism of chemoprevention (42). These studies reinforce 
the idea that dietary bioactives may not only influence colonic miRNA expression through their 
direct modulation, yet also influence secondary metabolites produced by gut microbiome (e.g., 
butyrate). 
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Gut Microbiome and Health 
The human gut microbiome consists of over 100 trillion bacteria, fungi and viruses. This 
plethora of microbes contributes more than 150 times more genetic information to the host than 
the human genome itself (43), playing a key role in host health and diseases through this genetic 
information. Advances in technology have improved the exploration of the human microbiome, 
allowing for the categorization of the gut microbiome per operational taxonomic (OTUs) units 
based on bacterial 16S ribosomal DNA. Now, vast studies are generating a map of the entire 
metagenome to better understand functional signatures of the gut microbiome, and assess one’s 
health status [i.e., Crohn’s disease (44)]. Diet is one of multiple factors contributing to the 
functional signatures of the gut microbiome. For instance, studies show long-term, high-fiber 
dietary exposure influences the gut microbiome in healthy young participants (45) and elderly 
participants (46), supporting the notion of diet as an important contributor to the health of the 
host’s gut microbiome.  
 
Types of fibers and dietary sources  
Dietary fibers have two subcategories, non-fermentable/insoluble and fermentable/soluble 
forms, which have varying impacts on the health of the host. The division of fibers is based off 
of differing physiochemical characteristics [e.g., origin, solubility and viscosity, fermentability, 
and chemical structure (47)].  Both soluble and insoluble dietary fibers have beneficial 
physiological effects on the host [e.g., body weight management (48)].  
Soluble fibers (e.g., pectin, guar gum, and some inulin) are present in whole grains, legumes, 
seeds and nuts, and some fruits and vegetables (e.g., carrots, apples) (49). One of the defining 
physiochemical characteristics of soluble fibers includes viscosity, which slows absorption of 
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nutrients in the intestine [e.g., glucose and lipids (47)] by creating a gel-like form. The capability 
of soluble fiber (e.g., pectin) to slow the absorption of glucose has been shown to aid 
preventative measures against metabolic diseases by controlling blood glucose levels (50).  
Insoluble dietary fibers [e.g., celluloses, hemicellulose, and fructans (51)] are present in nuts, 
beans, some whole grains (e.g., whole wheat flour and brown rice), and vegetables (52; 53). The 
defining physiochemical characteristics of insoluble fiber include a bulking effect and 
fermentation by the gut microbiome. Insoluble dietary fiber fermentation by the host gut 
microbiome produces short-chain fatty acids (SCFAs) as secondary by-products, aiding in a 
healthy microbial composition within the host gut microbiome (47). SCFAs are critical to the 
health of the host due to their potential immunological influences [e.g., butyrate’s capability to 
increase expression of antibacterial and host defense genes (54)].  A fiber-deprived gut 
microbiome has shown to increase disease susceptibility due to a reduction in protective mucus, 
which is utilized as a defense layer to block pathogens from entering the system (55), confirming 
the beneficial impact of fiber on the health of the host.  
Prebiotics were originally defined as “non-digestible compounds that, when consumed, 
induce changes in composition and/or activity of the gastrointestinal bacteria, thus causing 
benefit(s) upon host health” (56). Prebiotics include, but are not limited to, insoluble fibers. 
Consumption of prebiotics (e.g., β-glucan, xylooligosaccharides, and pure inulin) has shown to 
influence gut microbiota diversity and to increase production of SCFAs (52; 57; 58; 59). Positive 
functional characteristics of prebiotics have been reported including, but not limited to: (a) 
selective fermentation, (b) modulation of gut pH, (c) fecal bulking, (d) the prevention of gut 
colonization by pathogens, and (e) the control of putrefactive bacteria, thus reducing the host’s 
exposure to toxic metabolites (60).  
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Production of SCFAs 
SCFAs are produced by the gut microbiota through the fermentation of carbohydrates (50; 52) 
and other non-absorbable nutrients (57; 59). The most abundant SCFAs include acetate, propionate, 
and butyrate (61; 62), and represent 90-95% of all SCFAs produced in the colon (50; 58; 59). SCFAs 
are utilized by downstream bacterial species (cross feeding) and/or directly by the host as 
nutrient sources. Specifically, butyrate was frequently reported to be involved in other functions 
such as immune regulation (63), cell growth (64; 65), intestinal barrier function (66), and ion transport 
(67).  
 
Effects of dietary fibers on epithelial barrier functions 
The human intestine is a tubular organ, with the outer-most layer made of muscular tissue and 
the inner-most layer consisting of a single layer of enterocytes interfacing between the host inner 
tissue and the exterior intestinal environment. The single layered enterocytes are concatenated 
through tight junctions (TJs) to form a defense for food-borne pathogens or other ingested toxic 
compounds (68). The construction of TJs is maintained by enterocytes’ histological development 
and signaling pathways, such as tumor necrosis factor-α (69). Without this maintenance, TJs are 
the attack point for pathogenic bacteria to invade the host, resulting in permeability and leading 
to destructive intravenous electrolyte exchange, microbial dysbiosis, and diarrhea (69).  
Dietary fibers influence epithelial barrier functions through the production of SCFAs, 
specifically butyrate. Butyrate has a beneficial effect on epithelial barrier function, and is known 
to even nourish TJs (e.g., beta defensin, cingulin, ZO-1 and ZO-2 proteins) in chicken jejunal 
and cecal explants (70). It is suggested that butyrate enhances the TJs through activating 
Akt/mTOR pathways and ATP replenishment (71). Another potential function of dietary butyrate 
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includes the repression of interleukin 10 (IL-10) receptor-dependent claudin-2, thereby 
promoting barrier function by repressing the leak-flux mechanism responsible for diarrhea (72). 
 
Anti-inflammatory effects of dietary fibers 
The gut functions as one of the largest immune systems in humans, with physical (i.e., barrier 
function) and biochemical defenses (73). Once triggered, the pro-inflammatory response is the 
primary reaction to pathogens (74). Cells are then differentiated into multiple sub-types of 
immune cells as a natural response (75). These epithelial cells are constantly encountering 
pathogens and may frequently activate the immune response, resulting in immunologic diseases 
[e.g., inflammatory bowel disease (IBD) and autoimmune diseases (76; 77)]. Anti-inflammation 
(i.e., inhibitor of excessive inflammation) is needed to maintain immune homeostasis.  
Butyrate is known to act as an anti-inflammatory through its modulation of cytokine production, 
kinase activity, and immune-associated signaling pathways. Butyrate has been linked to multiple 
anti-inflammatory mechanisms, including the up-regulation of immunosuppressive IL-10 (78), 
nuclear factor (NF)-κB (79), and histone deacetylase (80; 81). Thus, supplementation of butyrate 
dense dietary fiber may counteract the severity of IBD and other inflammatory syndromes (79; 82; 
83).  
 
Phytochemicals and Gut Microbiome 
The term ‘phytochemical’ broadly encompasses all plant-derived chemicals. However, the 
term ‘phytochemical’ typically is used to refer to small non-essential nutrients with health-
promoting actions (84). About 90%-95% of phytochemicals reach the colon, and are transformed 
by the resident colonic microbiota (85), yielding bioavailable metabolites. The absorption of 
phytochemicals have proven beneficial to the health of the host, as being cardioprotective (86; 87), 
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and protective against glucose toxicity (88). Additionally, there has been a link with an increase in 
phytochemicals (i.e., polyphenols) and prevention in metabolic syndrome (89; 90), as well as a 
potential link to phytochemicals (i.e., hesperidin) and beneficial effects on colorectal cancer (91). 
Last, unabsorbed dietary phytochemicals can directly modulate the microbiota. For instance, 
phenolic compounds from tea leaves inhibited growth and adhesion of Clostridium Spp., E. coli,  
and S. Typhumurium (92).   
 
Carotenoids and their impacts on gut microbiome  
Carotenoids have been linked to a decreased risk of chronic diseases (93), and to the health of 
the gut microbiome. The effect of carotenoids, commonly found in apiaceous vegetables, on the 
gut microbiome has been examined previously in two studies. Ramos et al. analyzed the 
carotenoid source of Tucumã oil and its effect on microbial diversity and SCFA production in 
cows. Results indicated the use of Tucumã oil as a carotenoid source favorably shifted the gut 
microbiome. (94). Comparatively, a long-term randomized control study in humans analyzed the 
relationship between colonic mucosal bacteria and serum carotenoid concentrations. A shift in 11 
operational taxonomic units were associated with higher serum carotenoid levels, as well as other 
factors (e.g., body mass index, smoking, diet). Thus, indicating both behavioral and metabolic 
factors may impact the bioavailability of carotenoids to the gut microbiome (93). 
 
Glucosinolates and their impacts on gut microbiome 
The effect of glucosinolates, sulfur-containing dietary compounds, on the gut microbiome has 
only been examined previously in one study.  This gap in literature is surprising, as their benefits 
benefits against chronic disease, such as cancers, are well known (95; 96; 97). In this study, 
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Kaczmarek et al. found β-diversity alterations, indicating that bacterial communities were 
impacted by broccoli feeding(98). Additionally, broccoli consumption significantly altered a few 
key metabolic pathways: endocrine system, transport and catabolism, and energy metabolism (98). 
Clearly, further studies are warranted in the context of the disease preventive potential of 
cruciferous vegetables through gut microbiome modulation.  
 
Cruciferous Vegetables and Immune Functions  
The consumption of cruciferous vegetables has many health benefits, as they are a good 
source of glucosinolates and the SCFA butyrate when digested by gastrointestinal microbiota 
(e.g., Eubacterium rectale). In a recent study looking at fiber fermentation by gastrointestinal 
microbiota, vegetables within the cruciferous family (i.e., broccoli and cauliflower) ranked 
among the highest in total dietary fiber, substrate disappearance during fermentation, and SCFA 
production compared to other vegetables (i.e., carrot, celery, onion, radish, cucumber, and 
lettuce). Specifically, broccoli and cauliflower provided a good source of butyrate, a SCFA(99). 
Butyrate plays an essential role in immune defense via the maintenance of the epithelial barrier 
function, as previously noted. This beneficial effect on the intestinal epithelial barrier has been 
linked to therapeutic and preventive effects against a number of diseases [i.e., cardiovascular 
disease (100), hypertension (101), inflammatory disorders (102; 103; 104), and metabolic diseases (105)]. 
These beneficial effects include, but are not limited to, maintaining TJs within the epithelial wall 
(106), and mediating immune homeostasis via epithelial biosynthesis of retinoic acid (107). Thus, 
cruciferous vegetables (i.e., broccoli) continues to suggest an essential role in immune functions 
of an individual through the production of the SCFA butyrate via gastrointestinal microbiota 
digestion.  
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Additionally, cruciferous vegetables provide the main source of the glucosinolate class of 
phytochemicals in the diet (108). Glucosinolates can be hydrolyzed into various secondary 
metabolites (i.e., isothiocyanates) (109). With the link between cruciferous vegetables secondary 
metabolites and therapeutic/preventive effects on a multitude of diseases, the inclusion of these 
vegetables is vital in dietary intervention of the gut microbiome. More research on the impact of 
broccoli on the gut microbiome via secondary metabolite production (e.g., isothiocyanates and 
SCFA) is needed, as only one article has surfaced when searched. Specifically, the impact of 
broccoli’s role in immune function via gut microbiome modulation is relatively unknown, which 
is somewhat unexpected given its frequent consumption. However, the impact of the SCFA 
butyrate on immune function via the maintenance of the epithelial barrier has been well 
established in literature.  
 
Apiaceous Vegetables and Immune Functions  
Currently there is a gap in the literature regarding apiaceous vegetables and immune function, 
however some evidence exists for a role in reduction of inflammation. Apiaceous vegetable 
dietary constituents, such as falcarinol (FaOH) and falcarindiol (FaDOH, play a primary role in 
this reduction of inflammation. In a recent study, Kobaek-Larsen et al. reported anti-
inflammatory potential of apiaceous vegetables; it was found that FaOH and FaDOH inhibit NF-
κB signaling and its downstream inflammatory markers (e.g., COX-2) (110). Further, it was 
reported that FaOH reduces inflammation via modulating Nrf2 mRNA (111). Nrf2 is a 
transcription factor that upregulates the expression of antioxidant, anti-inflammatory, and 
cytoprotective enzymes (112). Additionally, in rats, FaOH and FaDOH modified intestinal 
microbiota composition by influencing the growth of Lactobacillus reuteri and Turicibacter (113). 
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Further investigation is needed regarding the relationship between apiaceous vegetables and 
inflammatory markers, especially in the context of gut microbial modulation. 
 
Crosstalk Between Gut MicroRNA and Gut Microbiome: Implications in Infants 
Studies have showed that the gut microbiota could be regulated by host-secreted miRNAs 
and, at the same time, the gut microbiota may affect the host by modulating various host 
miRNAs. To be specific, gut microbes and their metabolites possess a potential to regulate gene 
expression in intestinal epithelial cells via miRNA modulation and activation of multiple 
signaling pathways and diverse immune responses. This results in a bidirectional crosstalk 
between gut miRNA and the gut microbiome (114). In line with this, germ-free antibiotic-treated 
mice had significantly more fecal miRNA compared to controls with pathogen-free microbiota, 
indicating that gut microbes contribute to a specific miRNA signature (115). In the study, 
reduction of luminal miRNAs was associated with a shift in the gut microbiota. It was proposed 
that host-produced miRNAs are exported into the intestinal lumen as exosomes that are able to 
drive miRNA to the gut bacteria where they regulate bacteria gene transcription programs (115).  
As discussed above, clearly the gastrointestinal microbiota is a key factor in optimizing 
immunity; this is well accepted considering that diverse health benefits (in an array of disease 
models) can be achieved via modulation of gut microbiome. The foundation of one’s gut 
microbiome is contingent upon 1) acquiring microbiota via mother’s milk in infancy and 2) early 
dietary habits (116). In adults, short-term dietary intervention studies may show change within the 
microbiota, however maintaining microbial changes in a long-term intervention study has 
previously been shown to be difficult (117). Therefore, it is vital to establish a healthy gut 
microbiome as early as possible to ensure maximum health benefits throughout life (118). In the 
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first years of life (i.e., years 1-3) the microbiota and immune system are not yet matured or 
established (119), and therefore offer an opportune time to alter the gut microbiome via diet 
intervention. Thus, infancy proves a critical age group to target food-based intervention in hopes 
to reduce disease risk and increase immune function. Further, understanding the bidirectional 
crosstalk between gut miRNA and the gut microbiome would broaden our knowledge as to how 
the early establishment of the gut microbiome is mediated by host miRNAs, and if so, how diets 
play roles into mediating host miRNA. 
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Chapter 2 
Methods 
Specific Aim and Hypothesis 
This study aimed to determine the effects of short-term feeding of broccoli and carrot to 
infants on fecal miRNA. We hypothesized that broccoli and/or carrot would modulate fecal 
miRNA expression profiles, thereby potentially targeting key mRNAs involved in innate 
immunity.  
 
Study Design 
The study is a randomized controlled intervention design and each participant provided 
baseline data prior to their respective vegetable intervention. By the time of recruitment, 
participating infants were four to five months old thereby they could start the intervention (i.e., 
semi-solid vegetable food) at the age of six months. The justification for the intervention timing 
is two-fold: (1) World Health Organization (WHO) recommends starting solid foods at the age of 
six months (120), and (2) previous studies underscored the importance of the establishment of 
healthy intestinal microbiota in the first three years of life (119). The participants were followed 
for five days.  
This study consisted of three intervention groups: (1) control group (CON); (2) carrot group 
(CRT); and (3) broccoli group (BROC). The CON group participants consumed only breast milk 
and/or formula, without any vegetables for the intervention period. This would be consistent with 
the infant’s normal diet previously, as we excluded participants who had previous exposure to 
solid foods. During the intervention period, the CRT group and BROC group consumed carrot 
puree product and broccoli puree product, respectively, in addition to breast milk and/or formula. 
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For the vegetable puree, commercially available, frozen, pureed baby food products were 
purchased from Harvest to Highchair (Charleston, SC, USA). As the product was raw puree, the 
company did not provide nutritional information on their product’s packaging. According to the 
USDA database, 2 oz of raw broccoli provides 19 kilocalories, 1.5 g of total dietary fiber, 25.85 
mg of calcium, 0.4 mg of iron, 175 mg of potassium, 49.05 mg of vitamin C, and 17.05 µg 
vitamin A. A serving of 2 oz of raw carrots provides 23 kilocalories, 1.6 g of total dietary fiber, 
18.75 mg of calcium, 0.17 mg of iron, 182.2 mg of potassium, 3.35 mg of vitamin C, and 475.5 
µg vitamin A (121). Commercial baby food products were chosen for the study, rather than 
preparing the diet in the lab, thereby providing consistent, well controlled products and 
enhancing applicability of the study for the general public.  
The study lasted a total of five days, starting on the participant’s sixth month of age marker. 
On the first day (Day 0), diapers with fecal matter were collected for characterization of baseline 
miRNAs. Also, a food recall for the past 10 days (Day -10 through Day 0) was collected; the 
food recall was provided when subjects (in our study, parents of participating infants) agreed to 
participate in the study. Through the food recall, information such as amount, types (i.e., breast 
milk, formula or both), when, and how frequently the participating babies consumed breast milk 
and/or formula, was recorded. The food recall example is shown in Figure 1.  
The puree diets (either broccoli or carrot puree) were introduced from Day 1 through Day 3 (i.e., 
3 consecutive days: 2 oz per day). During the intervention period (i.e., Day 1 - Day 3), the CON 
group participants continued consuming breast milk and/or formula only. The WHO 
recommends complimentary food at age six to eight months to be offered 1-2 times a day (120). 
Therefore, our study offered 2 oz of vegetable puree a day; this allows for participating babies to 
consume the vegetable puree diets 1-2 times per day. All feeding information was collected 
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using our food recall form. The study design, diaper collection schedule, and dietary intervention 
information are depicted in Figure 2. This thesis is apart of a larger research project, which 
extends the intervention, diaper collection, and participants for a total of 30 days. Figure 2 shows 
the study design for the larger project; however, this thesis stops on Day 4.  
 
Participant Recruitment  
Participants were recruited in the Northwest Arkansas region (Washington and Benton 
counties, AR, USA) for one year (August, 2018- August, 2019). The recruitment was conducted 
via online news publication (e.g., University of Arkansas News), posted flyers, notification to 
local daycares, and personal recommendation. Inclusion criteria for participants included: four to 
five months old at the time of enrollment; willing to avoid over-the-counter and/or prescription 
medications; willing to exclude certain fruits, vegetables, and herbs from Day -10 through Day 8; 
willing to comply with the study protocol; and no plan to travel during the study duration. 
Exclusion criteria included: liver, kidney, or intestinal disorder history; necessary prescription 
medications; necessary over-the-counter medications; known allergies and/or intolerances to 
broccoli and carrots; plans to move out of Northwest Arkansas during the study period. If the 
participants had started solid foods prior to the intervention period, they were excluded from the 
study. The recruitment was not limited by milk source, breastfed nor formula fed infants. A total 
of 14 participants were recruited. Two participants dropped out due to occurrence of illness, and 
one participant failed to comply with the protocol, resulting in a total of 11 participants. The 11 
participants were randomly assigned to three groups: CON (n=3), CRT (n=4), and BROC (n=4). 
Participant demographics (i.e., ethnicity and sex) is provided in Table 2.  
 
 
18 
Participant Compliance 
As aforementioned, participant compliance was monitored using food recalls; each participant 
received two food recall forms for (1) Day -10 through Day -1; (2) Day 0 through Day 4. The 
first food recall aimed to gather information as to typical feeding patterns of the infants prior to 
the study intervention. The second food recall tracked how much of the intervention vegetable 
was consumed in addition to other diet consumption (e.g., breast milk and/or formula) during the 
period. In addition, fecal collection questionnaires were provided for asked to record time of 
diaper collection as well as stool sample conditions (e.g., consistency and color).  
 
Stool Collection  
Fecal collection was conducted in the best temperature sensitive way available for the study 
and participants. Each participant received a cooler with frozen ice packs for diaper collection; 
participants were instructed to keep the ice packs frozen until the day of the collection where 
they would put them in the cooler. When a dirty diaper occurred, the participants were instructed 
to put the diaper in a plastic zip-lock bag and placed in the cooler until the designated collection 
time. All fecal samples given that day were collected, transferred to the lab, and then stored at -
80°C until further analyses.  
 
Fecal RNA Extraction 
Fecal RNA from Day 0 and Day 4 was isolated using the RNeasy PowerMicrobiome kit 
(Qiagen, Hilden, Germany). In short, 0.25 g of stool was placed into a PowerBead tube, and then 
mixed with 650 μL PM1/βME at maximum vortex speed for 10 minutes. After, the tube was 
centrifuged at 13,000 × g for two minutes and the supernatant was transferred to a clean 
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collection tube. Next, 150 μL of IRS solution was incubated at 4°C for five minutes and 
centrifuged at 13,000 × g for one minute. Avoiding the pellet, the supernatant was transferred to 
a clean tube. A solution of 650 μL of PM3 and 650 μL of PM4 was added to each tube. The 
resulting supernatant was added to a MB RNA Spin Column and centrifuged at 13,000 × g for 
one minute; this step was repeated until all the supernatant had been processed through the spin 
column. Next, 650 μL of PM5 was added to the MB RNA Spin Column and centrifuged at 
13,000 × g for one minute. In the center of the column, 50 μL of DNase 1 solution was added 
and incubated at room temperature for 15 minutes. After, 400 μL of solution PM7 was added and 
centrifuged at 13,000 × g for one minute. Next, 650 μL of solution PM5 was added and 
centrifuged for one minute. Then, 650 μL of solution PM4 was added and centrifuged. After 
discarding the flow through, the MB RNA Spin Column was placed into a clean 2 mL collection 
tube. Lastly, 50 μL of RNase-free water was added to the center of the filter membrane and 
incubated for one minute. The water was centrifuged at 13,000 × g for one minute, and the RNA 
extraction was completed. The quality of isolated RNA was assessed using the conventional 
A260/280 ratio and the A260/230 ratio measurement (SpectraMax i3x; Molecular Devices, 
Sunnyvale, CA, USA). RNA samples were stored in test tubes in -80°C. 
 
Profiling Fecal MiRNAs 
Once we confirmed that all extracted RNA samples had a 280/260 ratio of ≥ 1.9 and a 
260/230 ratio of ≥ 1.8, extracted RNA was normalized to a single concentration (33 ng/µL) and 
then loaded into 96-well plates. The 96-well plates were sealed and shipped on dry ice to the 
University of Minnesota Genomic Center (Minneapolis, MN, USA). Fecal miRNA profiling was 
performed using the NanoString nCounter platform (NanoString, Seattle, WA, USA). The pre-
 
20 
built panel for human miRNA (nCounter Human v3 miRNA panel) was used, in which a total of 
827 different miRNA were analyzed.  
 
Statistical Analyses and Bioinformatics Analyses 
MiRNAs from Day 0 and Day 4 were analyzed using Nanostring nCounter platform to 
examine impacts of short-term dietary intervention of the vegetables on fecal miRNA 
expression. First, to ensure that differentially expressed miRNAs were due to dietary intervention 
and not by other factors, such as infant growth, we normalized the miRNA expression data with 
their respective baseline which is the data obtained at D0. After, the miRNAs differentially 
expressed in BROC or CRT were separately compared to the CON by a two-tailed Welch’s t 
test. A p-value of less than 0.05 was considered statistically significant (Microsoft Excel; 
Microsoft, Redmond, WA, USA). Data are expressed as mean ± standard error of mean (SEM).  
After, for the miRNA dataset, a short-list of differentially expressed genes (DEGs) was 
generated, using the criteria of miRNA showing a p-value < 0.05 and fold change > ± 1.5. The 
DEGs were subjected to the IPA software to predict potential mRNA targets, and potentially 
affected signaling pathways in response to BROC or CRT intervention. After, the predicted 
mRNA targets were subjected to PANTHER to assess over-represented, or under-represented 
biological processes and molecular functions in response to BROC or CRT intervention 
(available at pantherdb.org). We included the top 15 biological processes and molecular 
functions based on fold enrichment for CRT and BROC.  
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Chapter 3 
Results 
Effects of CRT Intervention 
Identification of differentially expressed miRNAs in response to CRT intervention 
In order to explore impact of CRT intervention on colon miRNA profile, we conducted 
miRNA expression profiling on infants’ fecal samples who were fed two ounces of carrots, per 
day, over three days. Based on the criteria mentioned above to be considered differentially 
expressed, a total of 22 miRNAs were included in our DEG list. Of the 22 miRNAs modulated, 
14 miRNAs were up-regulated and 8 miRNAs were down-regulated. Those up-regulated by the 
CRT intervention were miR-1253, miR-130a-3p, miR-146a-5p, miR-147a, miRNA-193-3p, 
miR-3127-5p, miR-3144-3p, miR-365b-5p, miR-374c-5p, miR-376b-3p,  miR-561-5p, miR-595, 
miR-603, and miR-627-5p. Down-regulated miRNAs by CRT intervention were miR-200c-3p, 
miR-2116-5p, miR-300, miR-320a-3p, miR-378b, miR-508-5p, miR-521, and miR-885-3p 
(Table 3).  
 
Computational analysis of miRNA from CRT intervention: prediction of target mRNAs 
The twenty-two miRNAs considered differentially expressed were subjected to IPA analysis 
in order to predict their downstream target mRNAs. Per IPA target prediction, eight miRNAs 
(miR–130a-3p, miR-146a-5p, miR-147a, miR-193a-3p, miR-200b-3p, miR-320b, miR-378a-3p, 
and miR-521) collectively targeted 132 mRNAs. It was predicted that some miRNAs targeted 
only one mRNA (e.g., miR-147a and miR-521) while the others targeted more than one mRNAs 
(e.g., miR-130a-3p, miR-320a-3p, miR-378b). Of note, it was predicted that miR-146a-5p targets 
a total of 80 mRNA from CRT intervention, which is the majority of the 132 mRNAs predicted 
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to be influenced by CRT. miR-193a-3p was predicted to target nine mRNAs [e.g., cyclin D1 
(CCND1), E2F transcription factor 6 (E2F6), erb-b2 receptor tyrosine kinase 4 (ERBB4), 
estrogen receptor 1 (ESR1), MCL1 apoptosis regulator, BCL2 family member (MCL1), 
plasminogen activator, urokinase (PLAU), protein tyrosine kinase 2 (PTK2), and ribosomal 
protein S6 kinase, 70kDa, polypeptide 2 (RPS6KB2)] whereas miR-200b targets 23 mRNAs 
[BRACA1 associated protein 1 (BAP1), engulfment and cell motility 2 (ELMO2), erbb2 
interacting protein (ERBIN), ERBB receptor feedback inhibitor 1 (ERRFI1), formin homology 2 
domain containing 1 (FHOD1), forkhead box F2 (FOXF2), gem (nuclear organelle0 associated 
protein 2 (GEMIN2), gse1 coiled-coil protein (GSE1), kelch-like family member 20 (KLHL20), 
myristoylated alanine rich protein kinase C substrate (MARCKS), phospholipase C gamma 
(PLCG1), protein phosphatase, Mg2+/Mn2+ dependent 1F (PPM1F), phosphatase and tensin 
homolog (PTEN), protein tyrosine phosphatase non-receptor type 12 (PTPN12), protein tyrosine 
phosphatase non-receptor type 13 (PTPN13), protein tyrosine phosphatase receptor type D 
(PTPRD), arginine-glutamic acid dipeptise (RE) repeats (RERE), WASP family member 3 
(WASF3), WD repeat domain 37 (WDR37), zinc finger E-box binding homebox 1 (ZEB1), zinc 
finger E-box binding homebox 2 (ZEB2), and zinc finger protein, FOG family member 2 
(ZFPM2)]. No mRNA targets were identified by IPA for the remaining 14 miRNAs (Table 3).  
 
Gene Ontology prediction of targeted mRNAs in CRT intervention 
The PANTHER over-representation tool was used to identify biological processes and 
molecular functions that were over-represented in the identified target mRNAs. The top 15 
identified biological processes and top 15 molecular functions of predicted target mRNAs in 
CRT intervention group are shown in the Table 5 and Table 6, respectively. Eight over- 
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represented biological processes had a fold enrichment greater than 100, with p <0.001. 
Additionally, five over-represented mRNA molecular functions had a fold enrichment greater 
than 60, with p <0.001. Of note, all of the top three molecular functions significantly over-
represented involved interleukin-1 activity, including ‘Interleukin-1, type I, activating receptor 
activity,’ ‘Interleukin-1 receptor activity,’ and ‘Interleukin-1 receptor binding.’ The targeted 
mRNA identified in our dataset are associated with ‘Interleukin-1, type I, activating receptor 
activity’ included interleukin 1 receptor type 1 (IL1R1) and interleukin 1 receptor like 2 
(IL1RL2). The identified target mRNAs, associated with ‘Interleukin-1 receptor activity’, 
include interleukin 1 receptor accessory protein (IL1RAP), IL1R1, IL1RL2, and interleukin 1 
receptor accessory protein-like 2 (IL1RAPL2) (Table 5). Lastly, molecular function ‘Interleukin-
1 receptor binding’ was associated with seven interleukin mRNAs. MRNAs identified include 
toll like receptor 9 (TLR9), IL1RAP, interleukin 36 alpha (IL36A), interleukin 1 family member 
10 (ILF10), interleukin 36 gamma (IL36G), interleukin 37 (IL37), interleukin 36 receptor 
antagonist (IL36RN), and interleukin 36 betta (IL36B) as targeted mRNA from our dataset. All 
biological processes and molecular functions were significantly different in terms of fold 
enrichment (Table 5 and Table 6).  
 
Effects of Broccoli Intervention 
Identification of differentially expressed miRNA in response to BROC intervention 
Similar to the CRT intervention, in order to identify global impacts of BROC intervention on 
colonic miRNAs, we conducted miRNA expression profiling using fecal samples from infants 
who received two ounces of broccoli, per day, over three days. Based on the criteria 
aforementioned, a total of 20 miRNAs were included in our list. Of the 20 miRNAs modulated, 
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nine miRNAs were up-regulated and 11 miRNAs were down-regulated. Those up-regulated by 
the BROC intervention were: miR-146a-5p, miR-190b, miR-22-3p, miR-3934-5p, miR-409-5p, 
miR-520f-3p, miR-548i, miR-573, and miR-612. Those down-regulated by BROC intervention 
were: miR-205-5p, miR-2116-5p, miR-329-3p, miR-361-5p, miR-3613-3p, miR-4425, miR-
4443, miR-499a-3p, miR-503-3p, miR-579-5p, and miR-596 (Table 4).  
 
Computational analysis of miRNA from BROC intervention: prediction of target mRNAs 
Twenty miRNAs met the screening criteria for IPA analysis to predict target mRNAs. Six 
miRNAs collectively targeted 101 mRNAs from our dataset. MiR-361-5p only targeted one 
mRNA while others were predicted to interact with multiple transcripts (e.g., miR-22-3p 
targeting five mRNAs [bone morphogenetic protein 7 (BMP7), ESR1, MYC associated factor 
(MAX), peroxisome proliferator activated receptor alpha (PPARA), and serum response factor 
(SRF)]. No targets were identified by IPA for the remaining 14 miRNAs (Table 4).   
 
Gene Ontology prediction of targeted mRNAs in BROC intervention 
Similarly, the PANTHER over-representation tool was utilized to identify biological 
processes and molecular functions that were significantly over-represented by the predicted 
mRNA targets in the BROC group. Table 7 and Table 8 display the top 15 enriched biological 
processes and the top 15 molecular functions of predicted mRNAs in broccoli-fed infants. Eight 
significantly over-represented mRNA biological processes had a fold enrichment greater than 
100, with p <0.001. In particular, ‘Negative regulation of natural killer cell differentiation 
involved in immune response’ and ‘Regulation of natural killer cell differentiation’, with 
identified mRNAs peptidoglycan recognition protein 2 (PGLYRP2) and peptidoglycan 
 
25 
recognition protein 1 (PGLYRP1), were found to be over-represented (Table 7). Additionally, 
three over-represented mRNA molecular functions had a fold enrichment greater than 100, with 
p <0.001; two molecular functions significantly over-represented, were involved with 
interleukin-1 activity. These included ‘Interleukin-1, type I, activating receptor activity’ with 
identified mRNAs IL1R1, IL1RAPL2, and ‘Interleukin-1 receptor activity’ with the identified 
mRNAs being IL1RAP, IL1R1, IL1RL, and IL1RAPL2. Lastly, ‘Interleukin-1 receptor binding’ 
was over-represented with a fold enrichment of 94.35 and a p<0.001; identified mRNAs from 
our dataset for ‘Interleukin-1 receptor binding’ included TLR9, IL1RAP, IL36A, ILF10, IL36G, 
IL37, interleukin 36 receptor antagonist (IL36RN), and IL36B (Table 8).  
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Chapter 4  
Discussion 
A global miRNA profiling analysis was conducted to determine effects of short-term feeding 
of broccoli and carrot on infants’ fecal miRNAs. In both CRT and BROC intervention, miR-
146a-5p was upregulated and was predicted to target 80 mRNAs per the IPA target prediction 
algorithm (Table 3 and Table 4). Functional characteristics of these predicted target mRNAs 
include tumor suppression, immune response, and inflammatory regulation.  
Regarding the immune response, the miR-146a-5p predicted to targeted signaling pathway is 
involved with TLR4; it is well established that the TLR4 signaling pathway plays an important 
role in activating the innate immune response (122). Similarly, TLR1 was a predicted target by 
miR-146a-5p, which plays a critical role in pathogen recognition as well activating innate 
immunity (123). Additionally, CRT also upregulated miR-130a-3p, which was predicted to target 
CSF1 (Table 3); CSF1 is critical for innate immunity and inflammatory processes through its 
capability to promote proinflammatory chemokines (123). These three predicted target mRNAs 
(i.e., TLR1, TLR4, and CSF1) show the potential for dietary supplementation of carrots to 
increase the innate immunity in infants. This is particularly important for infant participants, as 
an increase in innate immunity may decrease the rate of early infection early on (124; 125; 126).  
Other immune functions related miR-146a-5p’s target mRNAs include C-reactive protein 
(CRP), complement factor H (CFH), component of inhibitor of NF-κB kinase complex (CHUK), 
CD40 molecule (CD40), and TNF receptor associated factor 6 (TRAF6). CRP supports host 
defense through recognition of pathogens and damaged cells of the host and to initiate their 
elimination while CFH protein regulates host immune response through destroying pathogens, 
initiation of inflammatory responses, and removal of debris from cells and tissues (123). In 
 
27 
addition, CHUK (a target mRNA of miR-146a-5p) is known to participate in the canonical IKK 
complex by NF-κB activation and phosphorylates inhibitors of NF-κB on serine residues. NF-κB 
transitions to the nucleus and activates the transcription of hundreds of genes involved with 
immune response, growth control, or protection against apoptosis (123). CD40 protein is 
responsible for mediating a variety of immune and inflammatory responses; including T-cell 
dependent immunoglobulin class switching, memory B cell development, and germinal center 
formation (123). Last, TRAF6 may mediate CD40 signal, thus proving critical in immunoglobulin 
production regulation (123). This evidence in literature collectively proposes that carrot 
supplementation may aid in an infant’s capability to fight off disease after exposure, and could 
benefit the infant’s immunity. As an upregulation of miR-146a-5p is predicted to impact these 
genes directly, it is yet to be seen the reach of beneficial impacts enacted by these targeted 
mRNAs. 
CRT intervention may be related with tumor suppression as well. The miR-146a-5p (which 
was upregulated by the CRT) was predicted to target mRNAs, C-C motif chemokine ligand 8 
(CCL8), BRCA1 DNA repair associated (BRCA1), and cyclin dependent kinase inhibitor 3 
(CDKN3). The role of CCL8 still remains relatively unknown, however an increase of CCL8 
expression has been linked to multiple cancers (e.g., squamous cell (127), and cervical (128)). In 
contrast, BRCA1 is well known to provide instructions for tumor suppression proteins, therefore 
aiding in the maintenance of the rate of cell proliferation (123). Lastly, CDKN3 is related with cell 
cycle regulation and is known to be abnormally expressed (e.g., deleted, mutated, or 
overexpressed) in multiple cancers (123; 129; 130). In addition, in the context of cancer, predicted 
target mRNAs of miR-147a-5p include MCL1 apoptosis regulator, BCL2 family member 
(MCL1). MCL1 inhibits apoptosis in isoform 1, and its overexpression has been linked to lung 
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cancer progression and decrease survival rates (123; 131; 132). The miR-200c-3p, downregulated in 
the CRT intervention, was predicted to target BRCA1 associated protein 1 (BP1) and PTEN. 
Both of which act a tumor suppressors, regulating cell proliferation (123). As these predicted target 
mRNAs are related with tumor development as well as progression (e.g., cell proliferation), 
carrot supplementation has the potential to aid in preventing growth of tumors as infants’ bodies 
continue to grow and mature.  
Lastly, when comparing CRT to CON, there were multiple targeted mRNAs involved in 
inflammatory processes through miRNA upregulation and downregulation. Upregulation of miR-
146a-5p by CRT intervention was predicted to target multiple interleukins and cytokines (Table 
3), as well as other supportive mRNAs [e.g., chemokine receptor 3(CCR), Fas associated via 
death domain (FADD), interferon regulatory factor 5 (IRF5), nitric oxide synthase 2 (NOS2), 
and signal transducer and activator of transcription 1 (STAT1)]. FADD, IRF5, and NOS2 are 
involved in the synthesis and development of various interleukins and T-cells (123). Targeted 
mRNA CCR is associated with acute inflammatory response (133). STAT1 is associated with the 
IL-17 pathway, and interferon-alpha/beta and interferon-gamma signaling pathways. These 
pathways are critical in the immune defense against bacteria and viruses (123). Additionally, the 
upregulation of miR-130a-3p was predicted to target CSF1, which promotes the release of 
proinflammatory chemokines (123). These results suggestion the role of key miRNAs influenced 
by CRT may play in regulating inflammation, which is further supported by the previously 
established anti-inflammatory effects of apiaceous vegetables, such as carrots (110; 134).  
PANTHER analysis identified multiple biological processes and molecular functions, 
changed in the CRT intervention. Specific to immune function, the biological process ‘Positive 
regulation of interleukin-12 biosynthetic process’ had a significant fold change, and was 
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predicted to be influenced by mRNAs, TRAF6, LBT, TLR4. Interleukin 12 has an essential role 
in promoting T helper cell responses, therefore is found in cell-mediated immunity (135). 
Likewise, many predicted molecular functions support these immunological processes 
potentially influenced by CRT intervention. For example, the predictions of ‘Interleukin-1, type 
I, activating receptor activity’ targeted by IL1R1 and IL1RL2, ‘Interleukin-1 receptor activity’ 
targeted by IL1RAP, IL1R1, IL1RL2, and IL1RAPL2, and ‘Interleukin-1 receptor binding’ 
targeted by TLR9, IL1RAP, IL36A, ILF10, IL36G, IL37, IL36RN, and IL36B. The interleukin 1 
family (e.g., IL18, IL36, IL37, IL38) have been recognized for their pivotal roles in 
inflammation and immunity. Specifically, Interleukin 1 family members participates in 
therapeutic and preventative measures in autoimmunity and auto-inflammation (136). These 
predicted biological processes and molecular functions display the potential of CRT to influence 
inflammatory processes.  
Additionally, multiple biological processes involving macrophages were predicted to be 
influenced. Biological processes ‘Positive regulation of cellular response to macrophage colony-
stimulating factor stimulus,’ Positive regulation of response to macrophage colony-stimulating 
factor,’ ‘Regulation of response to macrophage colony-stimulating factor,’ and ‘Regulation of 
cellular response to macrophage colony-stimulating factor stimulus’ were predicted to be 
targeted by mRNAs, CSF1 and TLR4. Macrophages are central to the innate immune system, 
and plays a role in inflammation through release of cytokines (137). The prediction of these four 
macrophage biological processes are supported by the prediction of cytokine molecular 
functions. Molecular function ‘Cytokine receptor activity’ was related with IL12RN2, IL1RAP, 
CCR3, CXCR4, IL1R1, IL1RL2, and IL1RAPL2. Collectively, these biological processes and 
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molecular functions suggest the potential of CRT intervention to impact the human infants’ 
innate immunity.  
In the BROC intervention, we found a total of 20 miRNAs differentially expressed in fecal 
samples. Unique to the BROC intervention, we observed a downregulation in miR-205-5p. 
When subjected to IPA analysis, predicted targeted mRNAs of miR-205-5p included ATP1A1, 
INPPL1, and PTEN; as previously discussed, PTEN is a tumor suppressor (which can target by 
miR-200c-3p in the CRT intervention). This is unsurprising, as miRNAs have multiple targets, 
and multiple miRNAs can target a single mRNA (138). The three mRNAs predicted to be targeted 
by miR-205-5p proposes broccoli’s potential capability to impact multiple systems within the 
body (i.e., Na+/K+ ATPase protein pump, insulin regulation, and tumor suppression), thereby 
the potential to have protective or therapeutic effects on multiple diseases (e.g., cancer, blood 
pressure, diabetes). ATP1A1 is a gene that produces one part of Na+/K+ ATPase protein pump; 
this pump is particularly important in adrenal glands and influences blood pressure in the body 
(123). Additionally, INPPL1 encodes SH2-containing 5'-inositol phosphatase, which aids in the 
regulation of insulin (123). Together, these target mRNAs show the potential of miRNAs 
supporting broccoli’s impact on metabolic diseases (e.g., diabetes, hypertension) after 
phytonutrient absorption by the gut microbiome (139; 140). As childhood metabolic diseases are on 
the rise world-wide, the beneficial effects of INPPL1 and ATP1A1 on insulin regulation and 
blood pressure may aid in the health of infants through dietary interventions. This would be an 
important next step for future studies, in order to fully understand the reach of BROC 
intervention of the long-term health of an infant.  
Lastly, when BROC intervention had a predicted increase in immunoregulatory mRNAs, 
indicating a potential role in the immune system of the infant. Of note, the BROC also 
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upregulated miR-146a-5p, which targeted a total of 80 mRNA when subjected to IPA. As 
expected, the predicted target mRNAs were identical with those identified in the CRT 
intervention (e.g., TLR4, TLR1, CSF1, CRP, CFH, CHUK, CD40, and TRAF6) and many are 
discussed in detail above. Of note, IRAK1 is a putative serine/theonine kinase that is associated 
with interleukin-1 receptor, which is critical in innate immune response against pathogens (123). 
Additionally, CCR, FADD, IRF5, NOS2, and STAT1, indicate potential impacts of broccoli 
supplementation on inflammatory responses. In addition, the BROC group showed decreased 
expression of miR-361-5p when compared to the CON, which was predicted to target activation 
induced cytidine deaminase (AICDA). AICDA is a protein involved in somatic hypermutation, 
gene conversion, and class-switch recombination of immunoglobulin genes (123). Therefore, miR-
361-5p may play a role in helping the immune system adapt to foreign elements through 
targeting AICDA. Although broccoli’s influence on inflammation is well studied, this is the first 
time it has been predicted in human infants.   
In the PANTHER analyses, BROC intervention recognized the enrichment of biological 
processes: ‘Negative regulation of natural killer cell differentiation involved in immune 
response,’ ‘Negative regulation of natural killer cell differentiation,’ and ‘Regulation of natural 
killer cell differentiation involved in immune response.’ Natural killer cells are vital in our 
body’s defense system, and are utilized to attack infections and the growth of tumors (141). As 
natural killer cell differentiation depends on T and B cells (142), multiple molecular functions 
identified support this process; For example, ‘Lipopolysaccharide immune receptor activity’ is 
related with mRNAs TLR4 and PTAFR. The presence of bacterial lipopolysaccharide activates 
natural killer cells (143), where the natural killer cells can then attack the foreign invaders. 
Additionally, lipopolysaccharide is a stimulator of monokines, including interleukin 1 (143). 
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Molecular functions, enriched in the BROC group, associated include ‘Interleukin-1, type I, 
activating receptor activity’ (associated with IL1R1 and IL1RL2), ‘Interleukin-1 receptor 
activity’ (associated with IL1RAP, IL1R1, IL1RL, and IL1RAPL2), and ‘Interleukin-1 receptor 
binding’ (associated with TLR9, IL1RAP, IL36A, IL36G, IL37, IL36RN, and IL36B). These 
predicted biological functions and molecular processes further suggest the potential influence of 
BROC intervention to immunity in human infants.  
Although we were able to predict the impacts of CRT and BROC intervention on human 
infants’ immunity, there are multiple areas within this research that need to be further explored. 
In the future, validation of miRNAs and mRNAs expression, using more specific experimental 
technique (e.g., quantitative PCR analysis) after BROC and CRT intervention would be 
informative. Additionally, studies with larger sample sizes could increase accuracy and provide 
better statistical power. We had a sample size of 11 infants, which was a challenge to recruit. 
Northwest Arkansas is a collective of multiple, relatively small towns and cities, which had 
trouble accepting the invitation for infant participants. We were limited in willing participants, 
age-range of participants, and timeframe of the study. In a more populated area, and with more 
time, there is a possibility for a large sample size of infants to conduct the study. Lastly, we were 
not able to perfectly match macro/micronutrients/fiber contents of the carrot and broccoli purée. 
However, both broccoli and carrot contained similar fiber content (BROC = 1.5 g; CRT = 1.6 g). 
Given the small differences between them, the fiber intake might have been impacted more by 
other factors such as spillage.  
While there are a few limitations to our study, there are a few strengths. To our knowledge, 
our study is the first attempt that comprehensively profiled fecal miRNAs in response to CRT 
and BROC intervention in infant subjects. Additionally, we predicted mRNAs these miRNAs 
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influence through the IPA. In this, we were able to predict the extended potential effects of these 
miRNAs may have on the human infants. After, we exposed the vast amounts of predicted 
mRNAs to the PANTHER, predicting further into which biological processes and molecular 
functions may be impacted. As a result, this allows us to see the potential full affect CRT and 
BROC intervention may have on the health of human infants. Lastly, we were able to show that 
BROC and CRT intervention both have potential beneficial effects on infant immunity and, 
therefore, may help fight against common infant related infections.  
 
Conclusion 
In conclusion, we observed 22 miRNAs differentially expressed in CRT intervention, and 20 
miRNAs differentially expressed in BROC intervention.  When exposed to IPA and PANTHER, 
these differentially expressed miRNAs revealed a potential to impact multiple immune related 
functions. For example, miR-146a-5p in CRT intervention was predicted to target TLR4, which 
may influence biological processes involved with innate and acquired immunity (e.g., Positive 
regulation of interleukin-12 biosynthetic process). Additionally, miR-130a-3p in CRT 
intervention was predicted to target CSF1, which potentially impacts the innate immune system 
through CSF1 involvement in multiple biological processes involving macrophages. 
Comparatively, miR-146a-5p in BROC intervention was predicted to target PGLYRP2 and 
PGLYRP1. These mRNAs play a role in natural killer cells differentiation, therefore aiding in 
the immune systems capability to fight foreign invaders. Overall, our study provides potential 
evidence that CRT and BROC intervention impacts human infants’ miRNAs, and may lead to 
overall benefits in their immune system.  
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Appendix 
Table 1. Searched phytochemicals subcategories, sources, and references.1     
Phytochemicals 
Category: Subcategory: Source: Reference 
Flavonoids 
Anthocyanidins 
Acai Berry, Apple, Avocado, Banana, 
Blackberry, Blueberry, Cherries, 
Cranberry, Currants, Dates, Elderberry, 
Eggplant, Grapes, Grapefruit, 
Kiwifruit, Lingonberry, Pomegranate, 
Pear, Plum, Nuts, Raspberry, 
Strawberry, Tasmanian Peppers, Wine 
(144) 
Flavone -3-ols 
Apricots, Blackberry, Blueberry, 
Cranberry, Coffee, Chocolate, Grape 
Seeds, Kiwifruit, Nectarines, Nuts, 
Peaches, Plums, Rhubarb, Tea, Wine 
(144) 
Flavones 
Artichokes, Celery Seed Spice, Celery, 
Chicory, Honey, Juniper berry, 
Kumquats, Oregano, Olive Leaves, 
Pumpkin, Parsley, Pimento Peppers, 
Sweet Peppers, Sage, Thyme, 
(144) 
Flavonols 
Arugula, Asparagus, Bay Leaves, 
Capers, Cilantro, Chives, Cherries, 
Cranberries, Dill Weed, Elderberries, 
Juniper Berry, Okra, Parsley, Plum, 
Prickly, Pears, Saffron, Tarragon 
(144) 
Isoflavones Miso, Natto, Soy, Tempeh, Tofu (145) 
Carotenoids 
Carotenes  
(pro-vitamin A) 
Apricot, Brussel Sprouts, Cantaloupe, 
Cilantro, Kale, Romain Lettuce, 
Mango, Orange Pepper, Spinach, 
Butternut Squash, Watermelon 
(146) 
Xanthopylls  
(non-pro vitamin 
A) 
Artichoke, Asparagus, Broccoli, Egg, 
Kale, Romain Lettuce, Pistachio Nuts, 
Parsley, Red Pepper, Scallions, 
Spinach, Zucchini 
(146) 
Glucosinolates Isothiocyanates 
Broccoli, Brussel Sprouts, Cauliflower, 
Cabbage, Kale, Turnips 
(147) 
Phytosterols 
Epicholesterol Nuts, Seeds (148) 
6-Ketochilestanol 
Walnuts, Almonds, Peanuts, 
Hazelnuts, Macadamia Nuts 
(148) 
Cholesteryl 
Vegetable Oils, Spelt and Wheat 
Cereals 
(148) 
Allicins 
Organosulfur 
Compounds 
Garlic, Onions, Leeks 
(149) 
(150) 
1The databases PubMed and Google Scholar were utilized for the literature search.  
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Figure 1. Food Recall Example  
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Figure 2. Study Design Example  
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Table 2. Infant participant demographic  
 Category Number of Participants 
Ethnicity 
Asian 1 
White 3 
Native Indian or Alaskan Native & White 1 
Asian & White 1 
Non -Hispanic or Latino & White 5 
Milk Source 
Breastfed 8 
Formula Fed 3 
Both 1 
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Table 3. Effects of carrot intervention on miRNA  
Carrot DEmiR (1.5 Folds; p<0.05)1 
miRNA symbol miRBase accession Avg RQ ± SEM P-value vs control Target mRNA2 
hsa-miR-1253 MIMAT0005904 1.65 ± 0.14 0.017 Not Predicted 
hsa-miR-130a-3p MIMAT0000425 4.85 ± 0.59 0.004 ATG2B, CSF1, DICER1, HOXA5, MAFB, MEOX2, SMAD4, TAC1, ZFPM2 
hsa-miR-146a-5p MIMAT0000449 2.38 ± 0.28 0.016 
ATOH8, BLMH, BRCA1, C8A, CAMP, CCL8, CCNA2, CCR3, CD1D, CD40, CDKN3, CFH, CHUK, 
COL13A1, CRP, CXCL8, CXCR4, DMBT1, FADD, IFNA1/IFNA13, IFNB1, IL10, IL12RB2, IL1F10, 
IL1R1, IL1RAP, IL1RAPL2¸ IL1RL2, IL36A, IL36B, IL36G, IL36RN, IL37, IRAK1, IRAK2, IRF5, 
KIF22, KIR2DL1/KIR2DL3, KIR2DL2, LALBA,  LBP, LTB, LTF, MCM10, MCPH1, METTL7A, 
MMP16, MR1, NFIX,  NLGN1, NOS2, NOVA1, PA2G4, PBLD, PDGFRA, PDIK1L, PEX11G,PGLYR1, 
PGLYP2, PLEKHA4, POLE2, PRR15, PTAFR, PTGES2, RAD54L, S100A12, SDCBP2, SFTPD, STAT1, 
SYT1, TIMELESS, TLR1, TLR10, TLR4, TLR9, TMSB15A, TRAF6, TRIM14, UHRF1, VWCE 
hsa-miR-147a MIMAT0000251 2.19 ± 0.36 0.043 VEGFA 
hsa-miR-193a-3p MIMAT0000459 2.11 ± 0.21 0.029 CCND1, E2F6, ERBB4, ESR1, MCL1, PLAU, PTK2, RPS6KB2 
hsa-miR-200b-3p MIMAT0000617 0.38 ± 0.05 0.004 
ACE2, BAP1, ELMO2, ERBIN, ERRFI1, FHOD1, FOXF2, GEMIN2, GSE1, KLHL20, MARCKS, 
PLCG1, PPM1F, PTEN, PTPN12, PTPN13, PTPRD, RERE, WASF3, WDR37, ZEB1, ZEB2, ZFPM2 
hsa-miR-2116-5p MIMAT0011160 0.35 ± 0.11 0.047 Not Predicted 
hsa-miR-300 MIMAT0004903 0.61 ± 0.10 0.034 Not Predicted 
hsa-miR-3127-5p MIMAT0014990 3.13 ± 0.37 0.010 Not Predicted 
hsa-miR-3144-3p MIMAT0015015 1.98 ± 0.22 0.024 Not Predicted 
hsa-miR-320a-3p MIMAT0000510 0.56 ± 0.11 0.046 HSPB6, TAGLN, VIM 
hsa-miR-365b-5p MIMAT0022833 2.84 ± 0.48 0.031 Not Predicted 
hsa-miR-374c-5p MIMAT0018443 2.15 ± 0.36 0.050 Not Predicted 
hsa-miR-376b-3p MIMAT0002172 2.94 ± 0.58 0.045 Not Predicted 
hsa-miR-378b MIMAT0014999 0.13 ± 0.02 0.035 CASP9, IGF1R, ODC1, PDPK1, SUFU, TUSC2 
hsa-miR-508-5p MIMAT0004778 0.44 ± 0.16 0.036 Not Predicted 
hsa-miR-521 MIMAT0002854 0.18 ± 0.05 0.048 ERCC8 
hsa-miR-561-5p MIMAT0022706 2.06 ± 0.31 0.038 Not Predicted 
hsa-miR-595 MIMAT0003263 2.81 ± 0.49 0.033 Not Predicted 
hsa-miR-603 MIMAT0003271 2.90 ± 0.26 0.002 Not Predicted 
hsa-miR-627-5p MIMAT0003296 2.19 ± 0.27 0.040 Not Predicted 
hsa-miR-885-3p MIMAT0004948 0.27 ± 0.13 0.005 Not Predicted 
1Nanosting 2Ingunitive Pathway Analysis (IPA) 
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Table 4. Effects of broccoli intervention on miRNA  
Broccoli DEmiR (1.5 Folds; p<0.05)1 
miRNA symbol miRBase accession Avg RQ ± SEM P-value vs control Target mRNA2 
hsa-miR-146a-5p MIMAT0000449 3.07 ± 0.56 0.037 
ATOH8, BLMH, BRCA1, C8A, CAMP, CCL8, CCNA2, CCR3, CD1D, CD40, CDKN3, CFH, 
CHUK, COL13A1, CRP, CXCL8, CXCR4, DMBT1, FADD, IFNA1/IFNA13, IFNB1, IL10, 
IL12RB2, IL1F10, IL1R1, IL1RAP. IL1RAPL2, IL1RL2, IL36A, IL36B, IL36G, IL36RN, IL37, 
IRAK1, IRAK2, IRF5, KIF22, KIR2DL1/KIR2DL3, KIR2DL2, LALBA, LBP, LTB, LTF, 
MCM10, MCPH1, METTL7A, MMP16, MR1, NFIX, NLGN1, NOS2, NOVA1, PA2G4, PBLD, 
PDGFRA, PDIK1L, PEX11G, PGLYRP1, PGLYRP2, PLEKHA4, POLE2, PRR15, PTAFR, 
PTGES2, RAD54L, S100A12, SDCBP2, SFTPD, STAT1, SYT1, TIMELESS, TLR1, TLR10, 
TLR4, TLR9, TMSB15A, TRAF6, TRIM14, UHRF1, VWCE 
hsa-miR-190b MIMAT0004929 2.66 ± 0.46 0.035 Not Predicted 
hsa-miR-205-5p MIMAT0000266 0.45 ± 0.10 0.038 ATP1A1, DOK4, ERBB3, INPPL1, MED1, PRKCE, PTEN, TRPS1, VEGFA, ZEB1, ZEB2 
hsa-miR-2116-5p MIMAT0011160 0.32 ± 0.06 0.015 Not Predicted 
hsa-miR-22-3p MIMAT0000077 2.80 ± 0.44 0.034 BMP7, ESR1, MAX, PPARA, SRF 
hsa-miR-329-3p MIMAT0001629 0.38 ± 0.10 0.017 Not Predicted 
hsa-miR-361-5p MIMAT0000703 0.21 ± 0.06 0.004 AICDA 
hsa-miR-3613-3p MIMAT0017991 0.35 ± 0.05 0.008 Not Predicted 
hsa-miR-3934-5p MIMAT0018349 2.82 ± 0.44 0.025 Not Predicted 
hsa-miR-409-5p MIMAT0001638 2.31 ± 0.30 0.036 Not Predicted 
hsa-miR-4425 MIMAT0018940 0.34 ± 0.06 0.035 Not Predicted 
hsa-miR-4443 MIMAT0018961 0.63 ± 0.08 0.013 Not Predicted 
hsa-miR-499a-3p MIMAT0004772 0.45 ± 0.12 0.034 Not Predicted 
hsa-miR-503-3p MIMAT0022925 0.34 ± 0.07 0.003 Not Predicted 
hsa-miR-520f-3p MIMAT0002830 2.79 ± 0.41 0.022 Not Predicted 
hsa-miR-548i MIMAT0005935 1.97 ± 0.25 0.048 ERBB2, MTA1 
hsa-miR-573 MIMAT0003238 3.85 ± 0.84 0.047 Not Predicted 
hsa-miR-579-5p MIMAT0026616 0.54 ± 0.11 0.032 Not Predicted 
hsa-miR-596 MIMAT0003264 0.22 ± 0.09 0.027 Not Predicted 
hsa-miR-612 MIMAT0003280 1.65 ± 0.17 0.031 AKT2, TP53 
1Nanosting Analysis Results 2Ingunitive Pathway Analysis (IPA) Target mRNA.  
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Table 5. Signaling prediction of biological process for short-list miRNA in carrot-fed infants 
Panther GO Biological Process Terms 
N genes in 
reference 
genome 
dataset 
N 
genes 
in 
dataset 
Target mRNA 
identified in dataset 
Fold 
Enrichment 
P-value 
Negative regulation of natural killer cell differentiation 
involved in immune response 
3 2 PGLYRP2, PGLYP1 >100 < 0.001 
Negative regulation of natural killer cell differentiation 3 2 PGLYRP2, PGLYP1 >100 < 0.001 
Positive regulation of cell proliferation by VEGF-
activated platelet derived growth factor receptor 
signaling pathway 
3 2 VEGFA, PDGFRA >100 < 0.001 
VEGF-activated platelet-derived growth factor receptor 
signaling pathway 
3 2 CSF1, TLR4 >100 < 0.001 
Growth of symbiont in host 3 2 PGLYRP2, PGLYP1 >100 < 0.001 
Growth involved in symbiotic interaction 3 2 PGLYRP2, PGLYP1 >100 < 0.001 
Positive regulation of cellular response to macrophage 
colony-stimulating factor stimulus 
3 2 CSF1, TLR4 >100 < 0.001 
Positive regulation of response to macrophage colony-
stimulating factor 
3 2 CSF1, TLR4 >100 < 0.001 
Regulation of natural killer cell differentiation involved 
in immune response 
4 2 PGLYRP2, PGLYP1 76.66 < 0.001 
Receptor biosynthetic process 5 2 ACE2, IL10 61.33 < 0.001 
Regulation of cellular response to macrophage colony-
stimulating factor stimulus 
5 2 CSF1, TLR4 61.33 < 0.001 
Regulation of response to macrophage colony-
stimulating factor 
5 2 CSF1, TLR4 61.33 < 0.001 
Detection of bacterial lipoprotein 5 2 DMBT1, TLR1 61.33 < 0.001 
Positive regulation of interleukin-12 biosynthetic 
process 
8 3 TRAF6, LBT, TLR4 57.49 < 0.001 
Negative regulation of tumor necrosis factor 
biosynthetic process 
8 3 IL37, IL10, ERRFI1 57.49 < 0.001 
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Table 6. Signaling prediction of molecular function for short-list miRNA in carrot-fed infants  
Panther GO Molecular Function 
Terms 
N genes in 
reference 
genome 
dataset 
N genes 
in 
dataset 
Target mRNA identified in dataset 
Fold 
Enrichment 
P-value 
Interleukin-1, type I, activating 
receptor activity 
2 2 IL1R1, IL1RL2 >100 < 0.001 
Interleukin-1 receptor activity 7 4 IL1RAP, IL1R1, IL1RL2, IL1RAPL2 87.61 < 0.001 
Interleukin-1 receptor binding 17 8 TLR9, IL1RAP, IL36A, ILF10, IL36G, IL37, 
IL36RN, IL36B 
72.15 < 0.001 
NAD+ nuleotidase, cyclic 
ADP-ribose generating 
16 7 IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, 
IL1RAPL2, TLR1 
67.08 < 0.001 
NAD+ nucleosidase activity 16 7 IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, 
IL1RAPL2, TLR1 
67.08 < 0.001 
NAD(P)+ nucleosidase activity 16 7 IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, 
IL1RAPL2, TLR1 
67.08 <0.001 
Lipopeptide binding 10 3 TLR1, LBP, CD1D 45.99 < 0.001 
Platelet-derived growth factor 
receptor binding 
15 4 PTEN, VEGFA, PDGFRA, IL1R1 40.88 < 0.001 
Pattern recognition receptor 
activity 
24 6 TLR9, DMBT1, PGLYRP2, TLR4, PTAFR, 
PGLYRP1 
38.33 < 0.001 
Hydrolase activity, hydrolyzing 
N-glycosyl compounds 
38 7 IL1RAP, IL1R1, TLR4, TLR10, ILRL2, 
ILRAP2, TLR1 
28.24 < 0.001 
Lipopolysaccharide binding 33 6 CAMP, DMBT1, TLR4, PTAFR, LTF, LBP 27.88 < 0.001 
Tumor necrosis factor receptor 
binding 
32 4 TRAF6, STAT1, LTB, FADD 19.16 < 0.001 
Growth factor receptor binding 136 14 TRAF6, IL1RAP, IL36A, IL1F10, IL36G, 
PTEN, IL37, VEGFA, PDGFRA, ILR1, 
ERBB4, IL10, IL36RN, IL36B 
15.78 < 0.001 
Tumor necrosis factor receptor 
superfamily binding 
49 4 TRAF6, STAT1, LTB, FADD 12.52 < 0.001 
Cytokine receptor activity 99 7 IL12RN2, IL1RAP, CCR3, CXCR4, IL1R1, 
IL1RL2, IL1RAPL2 
10.84 < 0.001 
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Table 7. Signaling prediction of biological processes for short-list miRNA in broccoli-fed infants   
Panther GO Biological Process Terms 
N genes in 
reference 
genome 
dataset 
N genes 
in 
dataset 
Target mRNA 
identified in dataset 
Fold 
Enrichment 
P-value 
Metanephric mesenchymal cell proliferation involved in 
metanephros development 
3 2 BMP7, STAT1 >100 <0.001 
Kidney mesenchymal cell proliferation 3 2 BMP7, STAT1 >100 <0.001 
Negative regulation of natural killer cell differentiation 
involved in immune response 
3 2 PGLYRP2, PGLYRP1 >100 <0.001 
Negative regulation of natural killer cell differentiation 3 2 PGLYRP2, PGLYRP1 >100 <0.001 
Positive regulation of cell proliferation by VEGF-
activated platelet derived growth factor receptor signaling 
pathway 
3 2 VEGFA, PDGFRA >100 <0.001 
VEGF-activated platelet-derived growth factor receptor 
signaling pathway 
3 2 VEGFA, PDGFRA >100 <0.001 
Growth of symbiont in host 3 2 PGLYRP2, PGLYRP1 >100 <0.001 
Growth involved in symbiotic interaction 3 2 PGLYRP2, PGLYRP1 >100 <0.001 
Regulation of natural killer cell differentiation involved 
in immune response 
4 2 PGLYRP2, PGLYRP1 99.29 <0.001 
Epithelial cell proliferation involved in mammary gland 
duct elongation 
4 2 MED1, ESR1 99.29 <0.001 
Detection of bacterial lipoprotein 5 2 DMBT1, TLR1 79.43 <0.001 
Branch elongation involved in mammary gland duct 
branching 
4 2 MED1, ESR1 79.43 <0.001 
Positive regulation of interleukin-12 biosynthetic process 7 3 TRAF6, LTB, TLR4 74.47 <0.001 
Detection of other organism 14 5 
PGLYRP2, TLR4, 
PGLYRP1, TLR1, 
CD1D 
70.09 <0.001 
Regulation of interferon-alpha biosynthetic process 6 2 TLR9, IL10 70.09 <0.001 
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Table 8. Signaling prediction of molecular function for short-list miRNA in broccoli-fed infants    
Panther GO Molecular 
Function Terms 
N genes 
in 
reference 
genome 
dataset 
N 
genes 
in 
dataset 
Target mRNA identified in dataset 
Fold 
Enrichment 
P-value 
Interleukin-1, type I, 
activating receptor activity 
2 2 IL1R1, IL1RAPL2 >100 < 0.001 
Interleukin-1 receptor activity 7 4 IL1RAP, IL1R1, IL1RL, IL1RAPL2 >100 < 0.001 
N-acetylmuramoyl-L-alanine 
amidase activity 
4 2 PGLYP1, PGLYP2 >100 < 0.001 
Interleukin-1 receptor binding 17 8 
TLR9, IL1RAP, IL36A, IL36G, IL37, IL36RN, 
IL36B 
94.35 < 0.001 
NAD+ nucleosidase, cyclic 
ADP-ribose generating 
16 7 
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, IL1RAPL2, 
TLR1 
86.88 <0.001 
NAD+ nucleosidase activity 16 7 
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, IL1RAPL2, 
TLR1 
86.88 <0.001 
NAD(P)+ nucleosidase 
activity 
16 7 
IL1RAP, IL1R1, TLR4, TLR10, IL1RL2, IL1RAPL2, 
TLR1 
86.88 <0.001 
Lipopolysaccharide immune 
receptor activity 
5 2 TLR4, PTAFR 79.43 0.047 
ErB-3 class receptor binding 5 2 ERBB3, ERBB2 79.43 0.046 
Lipoteichoic acid binding 5 2 DMBT1, LBP 79.43 0.045 
Peptidoglycan immune 
receptor regulator 
5 2 PGLYP1, PGLYP2 79.43 0.045 
Lipopeptide binding 10 3 TLR1, LBP, CD1D 59.57 0.004 
Platelet-derived growth factor 
receptor binding 
15 4 PTEN, VEGFA, PDGFRA, IL1R1 52.57 0.004 
Pattern recognition receptor 
activity 
22 6 
TLR9, DMBT1, PGLYRP2, TLR4, PTAFR, 
PGLYRP1 
49.65 < 0.001 
Hydrolase activity, 
hydrolyzing N-glycosyl 
compounds 
38 8 
IL1RAP, MED1, IL1R1, TLR4, TLR10, IL1RL2, 
IL1RAPL2, TLR1 
41.81 < 0.001 
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Supplementary Figure 1. IRB Approval Form 
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Supplementary Figure 2. IRB Protocol Approval   
 
 
 
 
 
 
